Haemonetics Yönetim

Yönetim kriter kontrolleri 3/4

Haemonetics CEO'su Chris Simon, May2016 tarihinde atandı, in görev süresi 8.5 yıldır. in toplam yıllık tazminatı $ 11.55M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.4% maaş ve 90.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.55% ine doğrudan sahiptir ve bu hisseler € 22.68M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 7 yıldır.

Anahtar bilgiler

Chris Simon

İcra Kurulu Başkanı

US$11.5m

Toplam tazminat

CEO maaş yüzdesi	9.4%
CEO görev süresi	8.5yrs
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Chris Simon'un ücretlendirmesi Haemonetics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 28 2024	n/a	n/a	US$124m
Jun 29 2024	n/a	n/a	US$115m
Mar 30 2024	US$12m	US$1m	US$118m
Dec 30 2023	n/a	n/a	US$127m
Sep 30 2023	n/a	n/a	US$128m
Jul 01 2023	n/a	n/a	US$137m
Apr 01 2023	US$11m	US$1m	US$115m
Dec 31 2022	n/a	n/a	US$96m
Oct 01 2022	n/a	n/a	US$86m
Jul 02 2022	n/a	n/a	US$68m
Apr 02 2022	US$9m	US$945k	US$43m
Jan 01 2022	n/a	n/a	US$23m
Oct 02 2021	n/a	n/a	US$31m
Jul 03 2021	n/a	n/a	US$64m
Apr 03 2021	US$9m	US$963k	US$79m
Dec 26 2020	n/a	n/a	US$108m
Sep 26 2020	n/a	n/a	US$106m
Jun 27 2020	n/a	n/a	US$96m
Mar 28 2020	US$9m	US$937k	US$77m
Dec 28 2019	n/a	n/a	US$80m
Sep 28 2019	n/a	n/a	US$68m
Jun 29 2019	n/a	n/a	US$49m
Mar 30 2019	US$9m	US$894k	US$55m
Dec 29 2018	n/a	n/a	US$46m
Sep 29 2018	n/a	n/a	US$21m
Jun 30 2018	n/a	n/a	US$23m
Mar 31 2018	US$8m	US$858k	US$46m

Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 11.55M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.92M ).

Tazminat ve Kazançlar: Chris 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Chris Simon (60 yo)

8.5yrs

Görev süresi

US$11,545,113

Tazminat

Mr. Christopher A. Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016 and has been its Director since May 2016. He joined Haemoneti...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Simon	CEO, President & Director	8.5yrs	US$11.55m	0.55% € 22.7m
James D'Arecca	CFO, Executive VP & Financial Officer	2.6yrs	US$3.15m	0.0095% € 391.0k
Michelle Basil	Executive VP	7.7yrs	US$3.07m	0.039% € 1.6m
Josep Llorens	Executive Vice President of Global Manufacturing & Supply Chain	6.3yrs	US$2.43m	0.039% € 1.6m
Farris Maunsell	VP, Chief Accounting Officer & Principal Accounting Officer	2.1yrs	Veri yok	0.00027% € 11.1k
Olga Guyette	Senior Director of Investor Relations	5.1yrs	Veri yok	Veri yok
Rajeev Varma	Senior Vice President of Strategy & Corporate Development	1.6yrs	Veri yok	Veri yok
Laurie Miller	Senior VP & Chief Human Resources Officer	3.3yrs	Veri yok	0.023% € 963.7k
Jan Hartmann	Senior VP & Chief Medical Officer	1.6yrs	Veri yok	Veri yok
Stewart Strong	President of Global Hospital	5.2yrs	US$2.48m	0.036% € 1.5m
Kerri DiPietro	Senior Vice President of Global Quality Assurance	3.3yrs	Veri yok	Veri yok
Roy Galvin	President of Global Plasma & Blood Center	2.1yrs	Veri yok	0.0036% € 148.7k

3.3yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim: HAZ 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Simon	CEO, President & Director	8.2yrs	US$11.55m	0.55% € 22.7m
Robert Abernathy	Independent Director	7.1yrs	US$295.73k	0.036% € 1.5m
Michael Coyle	Independent Director	4.6yrs	US$283.73k	0.016% € 678.2k
Ellen Zane	Independent Chairman	6.8yrs	US$449.98k	0.024% € 1.0m
Claire Pomeroy	Independent Director	5.6yrs	US$269.95k	0.019% € 799.7k
Mark Kroll	Independent Director	18.8yrs	US$280.73k	0.032% € 1.3m
Charles Dockendorff	Independent Director	10.3yrs	US$292.95k	0.036% € 1.5m
Lloyd Johnson	Independent Director	3.3yrs	US$272.95k	0.012% € 476.3k
James Grotta	Member of Scientific Advisory Council	no data	Veri yok	Veri yok
Bryan Cotton	Member of Scientific Advisory Council	no data	Veri yok	Veri yok
Melissa Cushing	Member of Scientific Advisory Council	no data	Veri yok	Veri yok
Steven Frank	Member of Scientific Advisory Council	no data	Veri yok	Veri yok

7.0yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HAZ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).

Haemonetics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Haemonetics Corporation, Annual General Meeting, Jul 25, 2024

Haemonetics Corporation Elects Diane M. Bryant to Its Board of Directors

Haemonetics Corporation, Annual General Meeting, Aug 04, 2023

Executive VP & CTO recently sold €179k worth of stock

Insufficient new directors

Recent updates

Investor sentiment improves as stock rises 26%

Second quarter 2025 earnings released: EPS: US$0.67 (vs US$0.49 in 2Q 2024)

Haemonetics Corporation to Report Q2, 2025 Results on Nov 07, 2024

Insufficient new directors

First quarter 2025 earnings released: EPS: US$0.75 (vs US$0.81 in 1Q 2024)

Haemonetics Corporation to Report Q1, 2025 Results on Aug 08, 2024

Haemonetics Corporation Launches Limited Market Release of its New VASCADE MVP XL Mid-Bore Venous Closure Device

Haemonetics Corporation, Annual General Meeting, Jul 25, 2024

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025

Full year 2024 earnings released: EPS: US$2.32 (vs US$2.27 in FY 2023)

Haemonetics Corporation to Report Q4, 2024 Results on May 09, 2024

Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge

Haemonetics Corporation (NYSE:HAE) completed the acquisition of Advanced Cooling Therapy, Inc.

Haemonetics Corporation (NYSE:HAE) has entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc. for $160 million.

Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.65 in 3Q 2023)

Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024

Haemonetics Corporation to Report Q3, 2024 Results on Feb 08, 2024

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation Revises Revenue Guidance for the Fiscal Year 2024

Second quarter 2024 earnings released: EPS: US$0.49 (vs US$0.65 in 2Q 2023)

Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.

Haemonetics Corporation to Report Q2, 2024 Results on Nov 02, 2023

Haemonetics Corporation Elects Diane M. Bryant to Its Board of Directors

First quarter 2024 earnings released: EPS: US$0.81 (vs US$0.39 in 1Q 2023)

Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023

Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023

Haemonetics Corporation Receives FDA Clearance for Enhancements to NexSys PCS(R) Plasma Collection System

Haemonetics Corporation, Annual General Meeting, Aug 04, 2023

Executive VP & CTO recently sold €179k worth of stock

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2024

Full year 2023 earnings released: EPS: US$2.27 (vs US$0.85 in FY 2022)

Insufficient new directors

Haemonetics Corporation Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.65 (vs US$0.46 in 3Q 2022)

Investor sentiment improved over the past week

Haemonetics Corporation to Report Q3, 2023 Results on Feb 07, 2023

Second quarter 2023 earnings released: EPS: US$0.65 (vs US$0.29 in 2Q 2022)

Haemonetics Corporation Updates Revenue Guidance for the Year 2023

Haemonetics Corporation Appoints Maryanne Farris as Principal Accounting Officer

Haemonetics Corporation to Report Q2, 2023 Results on Nov 07, 2022

Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

Independent Director recently sold €580k worth of stock

First quarter 2023 earnings released: EPS: US$0.39 (vs US$0.087 loss in 1Q 2022)

Haemonetics Corporation (NYSE:HAE) announces an Equity Buyback for $300 million worth of its shares.

Haemonetics Corporation Announces Management Changes

Haemonetics Corporation to Report Q1, 2023 Results on Aug 10, 2022

Haemonetics Corporation, Annual General Meeting, Aug 05, 2022

CEO, President & Director recently sold €69k worth of stock

Haemonetics Corporation Announces Michelle L. Basil, Executive Vice President, General Counsel Has Decided to Transition, Effective October 31, 2022

Haemonetics Corporation Announces Retirement of Dan Goldstein as Vice President, Corporate Controller and Principal Accounting Officer, Effective August 9, 2022

Insider recently sold €61k worth of stock

Investor sentiment improved over the past week

Haemonetics Corporation Provides Earnings Guidance for the Fiscal Year 2023

Full year 2022 earnings released: EPS: US$0.85 (vs US$1.57 in FY 2021)

Haemonetics Corporation to Report Q4, 2022 Results on May 10, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Haemonetics Corporation Reaffirms Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings released: EPS US$0.29 (vs US$0.95 in 2Q 2021)

First quarter 2022 earnings released: US$0.087 loss per share (vs US$0.21 profit in 1Q 2021)

Independent Chairman Richard Meelia has left the company

Haemonetics Corporation(NYSE:HAE) dropped from Russell Midcap Index

Haemonetics Corporation(NYSE:HAE) dropped from Russell 1000 Dynamic Index

CEO, President & Director recently sold €59k worth of stock

Senior Vice President of Human Resources Jacqueline Scanlan has left the company

CEO, President & Director recently sold €123k worth of stock

Independent Director recently sold €66k worth of stock

Full year 2021 earnings released: EPS US$1.57 (vs US$1.51 in FY 2020)

Haemonetics Corporation Provides Earnings Guidance for the Fiscal Year 2022